Human medicines European public assessment report (EPAR): Pradaxa, dabigatran etexilate, Arthroplasty, Replacement;Venous Thromboembolism, Date of authorisation: 17/03/2008, Revision: 40, Status: Authorised

Human medicines European public assessment report (EPAR): Pradaxa, dabigatran etexilate, Arthroplasty, Replacement;Venous Thromboembolism, Date of authorisation: 17/03/2008, Revision: 40, Status: Authorised

Human medicines European public assessment report (EPAR): Zabdeno, ebola vaccine (Ad26.ZEBOV-GP [recombinant]), Hemorrhagic Fever, Ebola, Date of authorisation: 01/07/2020, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Zabdeno, ebola vaccine (Ad26.ZEBOV-GP [recombinant]), Hemorrhagic Fever, Ebola, Date of authorisation: 01/07/2020, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Mvabea, Ebola vaccine (MVA-BN-Filo [recombinant]), Hemorrhagic Fever, Ebola, Date of authorisation: 01/07/2020, Revision: 4, Status: Authorised

Human medicines European public assessment report (EPAR): Mvabea, Ebola vaccine (MVA-BN-Filo [recombinant]), Hemorrhagic Fever, Ebola, Date of authorisation: 01/07/2020, Revision: 4, Status: Authorised

Human medicines European public assessment report (EPAR): Blincyto, blinatumomab, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Date of authorisation: 23/11/2015, Revision: 18, Status: Authorised

Human medicines European public assessment report (EPAR): Blincyto, blinatumomab, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Date of authorisation: 23/11/2015, Revision: 18, Status: Authorised

Human medicines European public assessment report (EPAR): Ebglyss, Lebrikizumab, Dermatitis, Atopic, Date of authorisation: 16/11/2023, Status: Authorised

Human medicines European public assessment report (EPAR): Ebglyss, Lebrikizumab, Dermatitis, Atopic, Date of authorisation: 16/11/2023, Status: Authorised

Human medicines European public assessment report (EPAR): Carmustine medac (previously Carmustine Obvius), carmustine, Hodgkin Disease;Lymphoma, Non-Hodgkin, Date of authorisation: 18/07/2018, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR): Carmustine medac (previously Carmustine Obvius), carmustine, Hodgkin Disease;Lymphoma, Non-Hodgkin, Date of authorisation: 18/07/2018, Revision: 9, Status: Authorised

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

randomness